Corporate News: Zhejiang Anglikang Pharmac Trading Snapshot and Peer Performance
During the 24‑hour period concluding at 07:51 AM Central Europe on Thursday, 22 October 2026, Zhejiang Anglikang Pharmac (ticker 002940.SZ) remained unchanged, trading flat at 0 %. The current trading price on the most active exchanges sits at CNY 25.31 per share.
Key Market Metrics
- Shares Outstanding: 182.4 million
- Market Capitalisation: CNY 4.6 billion
- Volume Traded in Last 24 Hours: Approximately CNY 851 million
Since the close of the previous month, the stock has risen 7.54 %. The 200‑day simple moving average is CNY 26.51, providing a mid‑term reference point for investors. Over the past year, the highest recorded price reached CNY 48.90 on 14 November 2025, while the lowest fell to CNY 20.50 on 19 October 2026, underscoring the volatility inherent in the pharmaceutical sector.
Comparative Peer Analysis (Last 24 Hours)
| Peer | Ticker | Price | Market Cap (CNY bn) | Price/Earnings (PE) |
|---|---|---|---|---|
| Guangdong Silver Age Science | 300221.SZ | CNY 10.22 | 5.6 | 34.7 |
| Shanghai Geo Harbour Construction | 605598.SS | CNY 22.49 | 5.5 | – |
| Chengdu Xiling Power Science | 300733.SZ | CNY 13.44 | 5.6 | 49.44 |
| Hiecise Precision Equipment | 300809.SZ | CNY 21.92 | 5.5 | 25.26 |
| Shenzhen Topway Video | 002238.SZ | CNY 7.74 | 5.6 | – |
All listed peers experienced a flat performance of 0 % during the same 24‑hour window, mirroring the market’s overall equilibrium.
Interpretation for Stakeholders
The unchanged trading price suggests that current market sentiment toward Zhejiang Anglikang Pharmac remains stable, despite the broader sector exhibiting modest gains. The 200‑day moving average provides a useful gauge for trend assessment; a price below this average indicates a potential for further decline, whereas a price above may signal momentum.
Investors should note the company’s moderate market capitalisation relative to its peers, coupled with a relatively high price‑to‑earnings ratio when compared to some peers, indicating that the stock may be trading at a premium to earnings. The 52‑week high and low illustrate the asset’s price range, offering context for risk evaluation.
In sum, Zhejiang Anglikang Pharmac’s flat performance aligns with the broader corporate landscape in the 24‑hour period, while its key metrics provide a nuanced basis for both short‑term and long‑term investment considerations.
